Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Thyroid Associated News

Thyroid Associated News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Thyroid Associated. Real-time updates on events, politics, business and more.

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) - Horizon Therapeutics (NASDAQ:HZNP)

June 26, 2023
-- First and only medicine approved in Brazil for the treatment of active TED, a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease -- Horizon Therapeutics plc (NASDAQ:HZNP)
United States Vikram Karnani European Group On Grave Orbitopathy European Group On Grave Brazilian Health Regulatory Agency Drug Administration
Source: benzinga.com

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

June 22, 2023
-- At Week 24, 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with 11% of patients receiving placebo --
United States Yuji Hiromatsu Japan Pharmaceuticals Kurume University Medical Center European Group On Grave Orbitopathy Exchange Commission
Source: marketscreener.com

New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks

June 17, 2023
Horizon Therapeutics plc today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED, including among... | June 17, 2023
United States Terry Smith Jeffreyw Sherman European Group On Grave Orbitopathy Wk Kellogg Eye Center Endocrine Society Annual Meeting
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

June 17, 2023
-- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful... | June 17, 2023
United States Raymond Douglas Los Angeles Beth Scott Drug Administration Endocrine Society Annual Meeting
Source: marketscreener.com

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

June 5, 2023
-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT -- -- Two patients will share their real-world experience living with TED and being... | June 5, 2023
Olmsted County United States Jeffreyw Sherman Malini Gupta Duke University Health System European Group On Grave Orbitopathy
Source: marketscreener.com

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

May 1, 2023
Horizon Therapeutics plc today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease... | May 1, 2023
United States Elizabethhz Thompson Drug Administration Devices Agency Japan Pharmaceuticals European Group On Grave Orbitopathy
Source: marketscreener.com

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA®

May 1, 2023
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease act...
United States Erin Linnihan Elizabethhz Thompson Tina Ventura Maggie Fairchild Rachel Vann
Source: pharmiweb.com

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration

April 14, 2023
-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced
United States Tina Ventura Rachel Vann Tim Walbert European Group On Grave Orbitopathy Exchange Commission
Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science